全文获取类型
收费全文 | 436篇 |
免费 | 36篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 28篇 |
妇产科学 | 5篇 |
基础医学 | 24篇 |
口腔科学 | 7篇 |
临床医学 | 41篇 |
内科学 | 148篇 |
皮肤病学 | 13篇 |
神经病学 | 9篇 |
特种医学 | 70篇 |
外科学 | 34篇 |
综合类 | 18篇 |
预防医学 | 30篇 |
眼科学 | 15篇 |
药学 | 10篇 |
中国医学 | 1篇 |
肿瘤学 | 25篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 7篇 |
2020年 | 12篇 |
2019年 | 10篇 |
2018年 | 11篇 |
2017年 | 8篇 |
2016年 | 12篇 |
2015年 | 7篇 |
2014年 | 21篇 |
2013年 | 15篇 |
2012年 | 15篇 |
2011年 | 18篇 |
2010年 | 14篇 |
2009年 | 26篇 |
2008年 | 24篇 |
2007年 | 17篇 |
2006年 | 10篇 |
2005年 | 11篇 |
2004年 | 6篇 |
2003年 | 8篇 |
2002年 | 9篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 8篇 |
1998年 | 16篇 |
1997年 | 13篇 |
1996年 | 19篇 |
1995年 | 11篇 |
1994年 | 13篇 |
1993年 | 18篇 |
1992年 | 7篇 |
1991年 | 2篇 |
1990年 | 8篇 |
1989年 | 9篇 |
1988年 | 15篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 10篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1975年 | 2篇 |
排序方式: 共有478条查询结果,搜索用时 15 毫秒
51.
Marrow harvesting from normal donors 总被引:4,自引:2,他引:4
Buckner CD; Clift RA; Sanders JE; Stewart P; Bensinger WI; Doney KC; Sullivan KM; Witherspoon RP; Deeg HJ; Appelbaum FR 《Blood》1984,64(3):630-634
The experience at a single institution in harvesting marrow for allogeneic transplantation on 1,270 occasions from 1,160 normal donors is presented in detail, together with an analysis of all the donor complications. Four donors were less than 2 years old, and the youngest was 6 1/2 months. No special difficulties were encountered with these young donors. Hospitalization time was three days or less for 99% of the procedures. Six donors had life-threatening complications; three of a cardiopulmonary and two of an infectious nature, and one cerebrovascular embolic episode. Significant operative site morbidity, usually transient neuropathies, occurred in ten procedures. Ten percent of the donations were associated with transient postoperative fever of unknown origin. Increasing donor age was associated with a reduction of the cellularity of the marrow harvest. The use of stored autologous blood permitted the avoidance of blood bank transfusion in 81% of males, 69% of females, and 50% of children. It was concluded that the procedure was associated with a very low risk of complication, but that the involvement of normal donors in such an operation justifies stringent monitoring. 相似文献
52.
53.
Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus 总被引:8,自引:0,他引:8
Z Fronek L A Timmerman C A Alper B H Hahn K Kalunian B M Peterlin H O McDevitt 《Arthritis and rheumatism》1990,33(10):1542-1553
Susceptibility to systemic lupus erythematosus is associated with major histocompatibility complex (MHC)--encoded genes. We have used nucleotide sequence analysis to better define the disease-associated MHC alleles. HLA-DR2, DQw1, and especially the rare allele DQ beta 1. AZH confer high relative risk (RR = 14) for lupus nephritis in a Caucasian population of patients. Pilot studies using historical controls suggest that these genes also confer a high risk in non-Caucasian ethnic groups (RR = 24-78). We have found that DR4 is significantly decreased in patients with lupus nephritis. Fifty percent of the patients with lupus nephritis had either the DQ beta 1.1, the DQ beta 1.AZH, or the DQ beta 1.9 alleles. These alleles share amino acid residues that have been predicted to be the contact points for antigen and the T cell receptor. These HLA alleles appear to have a direct role in the predisposition to lupus nephritis, whereas DR4 may have a "protective" effect. 相似文献
54.
Immunologic heterogeneity of diffuse large cell lymphoma 总被引:2,自引:0,他引:2
Freedman AS; Boyd AW; Anderson KC; Fisher DC; Pinkus GS; Schlossman SF; Nadler LM 《Blood》1985,65(3):630-637
The cellular lineage of 57 diffuse large-cell lymphomas (DLCLs) was determined using a panel of monoclonal antibodies directed against lineage-restricted and -associated T, B, and monocyte antigens. The majority (82%) were of B cell lineage as determined by the expression of sig and/or B1, with the remaining 16% being of T cell lineage and 2%, of monocyte-myeloid lineage. By the expression of other B cell- restricted and -associated antigens, two major and two minor subgroups could be identified. These subgroups expressed the following phenotypes: (1) B1+B4+sIG+B2- (51%); (2) B1+B4+sIg+B2+ (29%); (3) B1+B4+sIg-B2+ (10%); and (4) B1+B4-sIg+B2- (10)%. The morphology of transformed lymphocytes, the weak to absent expression of the early B cell antigens B2 and sIgD, and the absence of the late B cell differentiation antigens PCA-1 and PC-1 suggested that these tumors were the neoplastic counterparts of normal B cells at the mid-stages of differentiation. Further support for the notion that B-DLCLs correspond to transformed B lymphocytes was concluded from the observation that B cells could be identified in normal spleen that expressed the cell surface phenotype and morphological appearance of the majority of B- DLCLs. 相似文献
55.
J. G. Hanly M. B. Urowitz L. Su J. Sanchez‐Guerrero S. C. Bae C. Gordon D. J. Wallace D. Isenberg G. S. Alarcón J. T. Merrill A. Clarke S. Bernatsky M. A. Dooley P. R. Fortin D. Gladman K. Steinsson M. Petri I. N. Bruce S. Manzi M. Khamashta A. Zoma J. Font R. Van Vollenhoven C. Aranow E. Ginzler O. Nived G. Sturfelt R. Ramsey‐goldman K. Kalunian J. Douglas K. Qiufen Qi K. Thompson V. Farewell 《Arthritis care & research》2008,59(5):721-729
Objective
To determine the short‐term outcome of neuropsychiatric (NP) events upon enrollment into an international inception cohort of patients with systemic lupus erythematosus (SLE).Methods
The study was performed by the Systemic Lupus International Collaborating Clinics. Patients were enrolled within 15 months of SLE diagnosis and NP events were characterized using the American College of Rheumatology case definitions. Decision rules were derived to identify NP events attributable to SLE. Physician outcome scores of NP events and patient‐derived mental component summary (MCS) and physical component summary (PCS) scores of the Short Form 36 were recorded.Results
There were 890 patients (88.7% female) with a mean ± SD age of 33.8 ± 13.4 years and mean disease duration of 5.3 ± 4.2 months. Within the enrollment window, 271 (33.5%) of 890 patients had at least 1 NP event encompassing 15 NP syndromes. NP events attributed to SLE varied from 16.5% to 33.9% using alternate attribution models and occurred in 6.0–11.5% of patients. Outcome scores for NP events attributed to SLE were significantly better than for NP events due to non‐SLE causes. Higher global disease activity was associated with worse outcomes. MCS scores were lower in patients with NP events, regardless of attribution, and were also lower in patients with diffuse and central NP events. There was a significant association between physician outcome scores and patient MCS scores only for NP events attributed to SLE.Conclusion
In SLE patients, the short‐term outcome of NP events is determined by both the characteristics and attribution of the events. 相似文献56.
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission 总被引:14,自引:9,他引:14
Freedman AS; Gribben JG; Neuberg D; Mauch P; Soiffer RJ; Anderson KC; Pandite L; Robertson MJ; Kroon M; Ritz J; Nadler LM 《Blood》1996,88(7):2780-2786
We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36% achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63% and 89% at 3 years, respectively, with a median follow-up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival. 相似文献
57.
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells 总被引:7,自引:4,他引:7
Urashima M; Ogata A; Chauhan D; Hatziyanni M; Vidriales MB; Dedera DA; Schlossman RL; Anderson KC 《Blood》1996,87(5):1928-1938
Interleukin-6 (IL-6), a product of bone marrow stromal cells (BMSCs), is a growth factor for multiple myeloma (MM) cells. Transforming growth factor-beta1 (TGF-beta1) is also produced by BMSCs and can regulate IL- 6 secretion by several tissues, including BMSCs. The present study was designed to characterize in vitro tumor growth regulation by TGF-beta1 in MM. Sorted CD38+CD45RA- MM cells secreted significantly more TGF- beta1 (8.2 +/- 2.0 ng/mL) than peripheral blood mononuclear cells (P < .001), splenic B cells (P < .001), and CD40 ligand (CD40L) pretreated B cells (P < .05). TGF-beta1 secretion by MM-BMMCs (3.8 +/- 0.9 ng/mL) was significantly greater than by N-BMMCs (1.2 +/- 0.1 ng/mL, P < .001). MM-BMSCs also secreted significantly more TGF-beta1 (6.6 +/- 2.5 ng/mL, n = 11) than N-BMSCs (4.4 +/- 0.6 ng/mL, P < .02, n = 10) and N- BMSC lines (3.9 +/- 0.2 ng/mL, P < .02, n = 6). TGF-beta1 secretion was correlated with IL-6 secretion in MM-BMSCs. Anti-TGF-beta1 monoclonal antibody both blocked IL-6 secretion by BMSCs and inhibited the increments in IL-6 secretion by BMSCs induced by MM cell adhesion. Moreover, exogenous TGF-beta1 upregulated IL-6 secretion by MM-BMSCs, normal BMSCs, and CD38+ CD45RA- MM cells, as well as tumor cell proliferation. This is in contrast to the inhibitory effect of TGF- beta1 on proliferation and Ig secretion of normal splenic B cells. Finally, retinoblastoma proteins (pRB) are constitutively phosphorylated in MM cells; TGF-beta1 either did not alter or increased pRB phosphorylation. pRB are dephosphorylated in splenic B cells and phosphorylated in CD40L triggered B cells in contrast to its effects on MM cells, TGF-beta1 decreased phosphorylation of pRB in CD40L treated B cells. These results suggest that TGF-beta1 is produced in MM by both tumor cells and BMSCs, with related tumore cell growth. Moreover, MM cell growth may be enhanced by resistance of tumor cells to the inhibitory effects of TGF-beta1 on normal B-cell proliferation and Ig secretion. 相似文献
58.
59.
Michelle Petri Daniel J. Wallace Alberto Spindler Vishala Chindalore Kenneth Kalunian Eduardo Mysler C. Michael Neuwelt Gabriel Robbie Wendy I. White Brandon W. Higgs Yihong Yao Liangwei Wang Dominique Ethgen Warren Greth 《Arthritis \u0026amp; Rheumatology》2013,65(4):1011-1021
Objective
To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE).Methods
In this multicenter, double‐blind, placebo‐controlled, sequential dose‐escalation study, patients were randomized 3:1 to receive IV sifalimumab (0.3, 1.0, 3.0, or 10.0 mg/kg) or placebo every 2 weeks to week 26, then followed up for 24 weeks. Safety assessment included recording of treatment‐emergent adverse events (AEs) and serious AEs. Pharmacokinetics, immunogenicity, and pharmacodynamics were evaluated, and disease activity was assessed.Results
Of 161 patients, 121 received sifalimumab (26 received 0.3 mg/kg; 25, 1.0 mg/kg; 27, 3.0 mg/kg; and 43, 10 mg/kg) and 40 received placebo. Patients were predominantly female (95.7%). At baseline, patients had moderate‐to‐severe disease activity (mean SLE Disease Activity Index score 11.0), and most (75.2%) had a high type I interferon (IFN) gene signature. In the sifalimumab group versus the placebo group, the incidence of ≥1 treatment‐emergent AE was 92.6% versus 95.0%, ≥1 serious AE was 22.3% versus 27.5%, and ≥1 infection was 67.8% versus 62.5%; discontinuations due to AEs occurred in 9.1% versus 7.5%, and death occurred in 3.3% (n = 4) versus 2.5% (n = 1). Serum sifalimumab concentrations increased in a linear and dose‐proportional manner. Inhibition of the type I IFN gene signature was sustained during treatment in patients with a high baseline signature. No statistically significant differences in clinical activity (SLEDAI and British Isles Lupus Assessment Group score) between sifalimumab and placebo were observed. However, when adjusted for excess burst steroids, SLEDAI change from baseline showed a positive trend over time. A trend toward normal complement C3 or C4 level at week 26 was seen in the sifalimumab groups compared with baseline.Conclusion
The observed safety/tolerability and clinical activity profile of sifalimumab support its continued clinical development for SLE.60.